Physicochemical Properties
| Molecular Formula | C22H27NO7 |
| Exact Mass | 417.178 |
| CAS # | 1054312-81-0 |
| PubChem CID | 9823255 |
| Appearance | Typically exists as solid at room temperature |
| Density | 1.33±0.1 g/cm3(Predicted) |
| Boiling Point | 572.0±50.0 °C(Predicted) |
| LogP | 1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 8 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 30 |
| Complexity | 737 |
| Defined Atom Stereocenter Count | 4 |
| SMILES | O=C(C)O[C@@H]1C(OC)=C2[C@@H]3CC4C=CC(=C(O)C=4[C@]2(CCN3)C[C@@H]1OC(C)=O)OC |
| InChi Key | XAQZCUNTDGRIEM-AKUOHEDMSA-N |
| InChi Code | InChI=1S/C22H27NO7/c1-11(24)29-16-10-22-7-8-23-14(18(22)21(28-4)20(16)30-12(2)25)9-13-5-6-15(27-3)19(26)17(13)22/h5-6,14,16,20,23,26H,7-10H2,1-4H3/t14-,16-,20-,22-/m0/s1 |
| Chemical Name | [(1S,9S,12S,13S)-12-acetyloxy-3-hydroxy-4,11-dimethoxy-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5,10-tetraen-13-yl] acetate |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vitro | FK-3000 (0-5 μg/mL; 48 h) restricts the growth of cells; the IC50 values for MCF-7, PC-3, A-431, HT-29, and CT-26 cells are, in turn, 0.52 μg/mL, 0.77 μg/mL, 0.22 μg/mL, 2.70 μg/mL, and 1.90 μg/mL[1]. MDA-MB-231 cells undergo apoptosis when exposed to FK-3000 (0.5-5.0 μg/mL; 24-48 h) in a dose- and time-dependent manner[1]. In MDA-MB-231 and MCF-7 cells, FK-3000 (0.5-5.0 μg/mL; 24-48 h) promotes G2/M phase arrest in a dose- and time-dependent manner [2]. In MDA-MB-231 cells, FK-3000 (0.5-5.0 μg/mL; 60-120 min or 24-48 h) decreases COX-2 expression and NF-κB phosphorylation levels [1]. In MDA-MB-231 cells, FK-3000 (5.0 μg/mL; 120 min) efficiently inhibits NF-κB's translocation from the cytoplasm to the nucleus [1]. |
| ln Vivo | In an MDA-MB-231 xenograft mice model, FK-3000 (1 mg/kg/day; ip daily for 24 d) suppresses tumor growth without exhibiting any harm [1]. FK-3000 (10–25 mg/kg; po for 10 d) considerably postpones skin damage, prevents more damage from developing, and increases the average survival duration of HSV-1-infected mice [3]. |
| References |
[1]. FK-3000 isolated from Stephania delavayi Diels. inhibits MDA-MB-231 cell proliferation by decreasing NF-κB phosphorylation and COX-2 expression. Int J Oncol. 2015;46(6):2309-16. [2]. 6,7-di-O-acetylsinococuline (FK-3000) induces G2/M phase arrest in breast carcinomas through p38 MAPK phosphorylation and CDC25B dephosphorylation. Int J Oncol. 2015 Feb;46(2):578-86. [3]. In vivo antiviral activity of Stephania cepharantha against herpes simplex virus type-1. Phytother Res. 2001 Sep;15(6):497-500. [4]. Development of a LC-MS method for quantification of FK-3000 and its application to in vivo pharmacokinetic study in drug development. J Pharm Biomed Anal. 2012 Nov;70:587-91. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |